Patents Issued in August 14, 2018
-
Patent number: 10045993Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.Type: GrantFiled: June 22, 2015Date of Patent: August 14, 2018Assignee: CTC BIO, INC.Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Su-Jun Park, Jiyeong Han, Myeongcheol Kil, Min Seop Kim
-
Patent number: 10045994Abstract: The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases.Type: GrantFiled: June 13, 2014Date of Patent: August 14, 2018Assignee: SERVICIO ANDALUZ DE SALUDInventors: José Antonio Pérez Simón, María Victoria Barbado González
-
Patent number: 10045995Abstract: The present invention relates to an epidithiodioxopiperazine derivative represented by the following Chemical Formula 1 or its reduced derivative; a method for preparing a compound represented by Chemical Formula 1 having improved intracellular permeability and mimicking the activity of 2-Cys-Prx in its reduced form in the cells; a pharmaceutical composition for preventing or treating vascular diseases comprising an epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient; a drug delivery device for local administration including the pharmaceutical composition; and a pharmaceutical composition for inhibiting melanoma metastasis comprising the epidithiodioxopiperazine compound or its derivatives or pharmaceutically acceptable salts thereof as an active ingredient.Type: GrantFiled: February 23, 2017Date of Patent: August 14, 2018Assignee: EWHA University Industry-Collaboration FoundationInventors: Sang Won Kang, Dong Hoon Kang, Doo Jae Lee
-
Patent number: 10045996Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.Type: GrantFiled: March 16, 2011Date of Patent: August 14, 2018Assignee: NOVALIQ GMBHInventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
-
Patent number: 10045997Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.Type: GrantFiled: September 28, 2016Date of Patent: August 14, 2018Assignee: ALLERGAN, INC.Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
-
Patent number: 10045998Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.Type: GrantFiled: December 9, 2014Date of Patent: August 14, 2018Assignee: BASF SEInventors: Tiziana Chiodo, Beate Salvador, Marcus Vossen, Andreas Hafner, Tobias Hintermann, Martin Szelagiewicz, Fritz Blatter, Martin Viertelhaus, Walter Weishaar
-
Patent number: 10045999Abstract: The invention relates to the use of an anabolic amino acid derivative stimulus acting in combination with vitamin D for the manufacture of a medicament or nutritional composition for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal.Type: GrantFiled: June 25, 2015Date of Patent: August 14, 2018Assignee: N. V. NutriciaInventors: Marion-Eve Adeline Jourdan, Yvette Charlotte Luiking, George Verlaan, Sovianne Ter Borg
-
Patent number: 10046000Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.Type: GrantFiled: May 24, 2017Date of Patent: August 14, 2018Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
-
Patent number: 10046001Abstract: Compositions, kits, and methods for reducing intraocular pressure (IOP) in a subject (e.g., human) include at least one naturally occurring or synthesized version or analog thereof of a lipid (e.g., a phosphoserine, a phosphocholine, a psychosine or other glycolipid) that is endogenous to non-glaucomatous aqueous humor in a subject and that lowers IOP in the subject, in a therapeutically effective amount for promoting aqueous outflow through TM in at least one eye of the subject and reducing IOP in the subject. The compositions can be used for, e.g., treating glaucomas, including, for example, primary open angle glaucoma (POAG) and normal tension glaucoma (NTG).Type: GrantFiled: December 4, 2014Date of Patent: August 14, 2018Assignee: UNIVERSITY OF MIAMIInventors: Richard K. Lee, Sanjoy K. Bhattacharya
-
Patent number: 10046002Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.Type: GrantFiled: November 17, 2016Date of Patent: August 14, 2018Assignee: SYNTRIX BIOSYSTEMS INC.Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
-
Patent number: 10046003Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.Type: GrantFiled: April 2, 2014Date of Patent: August 14, 2018Assignee: INDUS BIOTECH PRIVATE LIMITEDInventors: Sunil Bhaskaran, Mohan Vishwaraman
-
Patent number: 10046004Abstract: The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).Type: GrantFiled: April 9, 2015Date of Patent: August 14, 2018Assignee: Shanghai KE Pharmaceutical Co., LTDInventors: Minsheng Zhu, Jie Sun, Yang Pan
-
Patent number: 10046005Abstract: A composition and associated method for treating a hepatitis C virus (HCV) infection in a subject who is human being. The composition includes: an anti-viral agent and/or a protease inhibitor; a polymerase inhibitor; one or more viral entry inhibitors; and one or more anti-fibrotic agents and/or anti-hemolytic agents including one or more Polyphenols and/or one or more Thiols. The composition may also include one or more sulfated oligosaccharide or non-anticoagulant glycosaminoglycans (GAGs). The method administers, to the subject, a therapeutic dose of the composition to treat the subject for the HCV infection.Type: GrantFiled: August 11, 2016Date of Patent: August 14, 2018Inventor: Shaker A. Mousa
-
Patent number: 10046006Abstract: Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID NO: 8 (IDX9059); SEQ ID NO: 14 (IDX9052); SEQ ID NO: 7 (IDX9054); SEQ ID NO: 6 (IDX9045); SEQ ID NO: 1 (IDX9005); SEQ ID NO: 9 (IDX9074); SEQ ID NO: 3 (IDX9022); SEQ ID NO: 2 (IDX9010); SEQ ID NO: 4 (IDX9030); and SEQ ID NO: 13 (IDX0150).Type: GrantFiled: October 10, 2014Date of Patent: August 14, 2018Assignee: InDex Pharmaceuticals ABInventors: Charlotte Admyre, Lars-Göran Axelsson, Oliver Von Stein, Arezou Zargari
-
Patent number: 10046007Abstract: The invention generally relates to methods of treating short telomere disorders using known compounds and pharmaceutical compositions comprising same. More specifically, the disclosed methods comprise, in one aspect, the step of administering to the subject an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, thereby treating the subject for the short telomere disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: June 24, 2016Date of Patent: August 14, 2018Assignee: Prescient Pharma, LLCInventors: Pavel Idelevich, Yanming Wang
-
Patent number: 10046008Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.Type: GrantFiled: September 10, 2015Date of Patent: August 14, 2018Assignee: The Trustees of the University of PennsylvaniaInventors: Carl H. June, Bruce L. Levine, Anne Chew, Stephen J. Schuster
-
Patent number: 10046009Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.Type: GrantFiled: February 12, 2015Date of Patent: August 14, 2018Assignee: ERYTECH PHARMAInventors: Yann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
-
Patent number: 10046010Abstract: A method of generating MSCs which secrete neurotrophic factors (NTFs) comprising incubating a population of undifferentiated mesenchymal stem cells (MSCs) in a differentiating medium comprising basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), heregulin and cAMP.Type: GrantFiled: August 4, 2013Date of Patent: August 14, 2018Assignee: BrainStorm Cell Therapeutics Ltd.Inventors: Yael Gothelf, Yosef Levy, Alex Burshtein
-
Patent number: 10046011Abstract: The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).Type: GrantFiled: December 14, 2013Date of Patent: August 14, 2018Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Yufang Shi, Guangwen Ren, Liying Zhang
-
Patent number: 10046012Abstract: The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation.Type: GrantFiled: November 9, 2015Date of Patent: August 14, 2018Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Songtao Shi, Byoung-Moo Seo, Masako Miura
-
Patent number: 10046013Abstract: Disclosed is an oral delivery system that overcomes major barriers encountered in the gastrointestinal tract, particularly rapid proteolytic degradation and low intestinal permeability. Provided is a method for oral delivery of an engineered microorganism to a mammal where the microorganism produces a macromolecule having a desired bioavailability outcome.Type: GrantFiled: March 8, 2012Date of Patent: August 14, 2018Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Casim Ali Sarkar, Ting Wun Ng
-
Patent number: 10046014Abstract: The present invention relates to the cosmetic use of a lysate of a bacterium or bacteria belonging to the Vitreoscilla sp. genus (in particular the species: Vitreoscilla filiformis) in a complete fermentation medium, as an active agent for preventing and/or treating dandruff conditions of the scalp, including dandruff conditions of the scalp associated with a prevalence of pathogenic microorganisms on the scalp and/or an imbalance of the scalp ecoflora.Type: GrantFiled: April 5, 2012Date of Patent: August 14, 2018Assignee: L'OREALInventors: Pascal Hilaire, Yann Mahe, Richard Martin
-
Patent number: 10046015Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.Type: GrantFiled: November 21, 2016Date of Patent: August 14, 2018Assignee: 4D Pharma Research LimitedInventors: Imke Elisabeth Mulder, Amy Beth Holt, Seanin Marie McCluskey, Grainne Clare Lennon, Suaad Ahmed
-
Patent number: 10046016Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.Type: GrantFiled: July 28, 2014Date of Patent: August 14, 2018Assignees: The Regents of the University of California, Integrative Gene TherapeuticsInventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
-
Patent number: 10046017Abstract: Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals.Type: GrantFiled: January 9, 2014Date of Patent: August 14, 2018Assignee: Nestec S.A.Inventors: Ignatius Szeto, Peifang Zhang, Weiguo Zhang, Junkuan Wang, Chieh Jason Chou
-
Patent number: 10046018Abstract: Methods and formulations for increasing the water solubility and/or bioavailability of a phytocannabinoid compound is disclosed herein. In one example, a water-soluble phytocannabinoid formulation can comprise a phytocannabinoid; a non-ionic surfactant; and optionally, water. The weight ratio of phytocannabinoid content to non-ionic surfactant can be from 1:10,000 to 1:5.Type: GrantFiled: March 5, 2018Date of Patent: August 14, 2018Inventor: Eric Kuhrts
-
Patent number: 10046019Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.Type: GrantFiled: September 11, 2016Date of Patent: August 14, 2018Assignees: YUNGJIN PHARMACEUTICAL CO., LTD, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Yongnam Lee, Ji-seok Yoo, Dae-hee Shin, Byung-hwan Ryoo, Sei-ryang Oh, Kyung-seop Ahn, Hyeongkyu Lee, Ok-kyoung Kwon, Doo-young Kim, Jung-hee Kim, Hyuk-hwan Song
-
Patent number: 10046020Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.Type: GrantFiled: December 14, 2016Date of Patent: August 14, 2018Inventor: Thomas Luger
-
Patent number: 10046021Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.Type: GrantFiled: December 1, 2015Date of Patent: August 14, 2018Assignee: TPCERA LTD.Inventors: Yehuda Shoenfeld, Miriam Blank
-
Patent number: 10046022Abstract: Provided are a synthetic peptide that increases the radiosensitivity of tumor cells and a pharmaceutical composition containing that synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a radiosensitizing peptide sequence including the following amino acid sequence: CX2X3KX5X6X7X8C (wherein, X2 represents K or R, X3 represents S or A, X5 represents S or A, X6 represents R or G, X7 represents R or D and X8 represents S or P); or, a modified amino acid sequence in which one, two or three amino acid residues are substituted, deleted and/or added in that amino acid sequence. In addition, the pharmaceutical composition provided by the present invention is a composition used to increase the sensitivity of tumor cells to radiation in tumor radiation therapy, and contains the synthetic peptide described above.Type: GrantFiled: May 25, 2016Date of Patent: August 14, 2018Assignee: TOAGOSEI CO. LTD.Inventors: Nahoko Baileykobayashi, Noriko Usami, Tetsuhiko Yoshida
-
Patent number: 10046023Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.Type: GrantFiled: November 17, 2016Date of Patent: August 14, 2018Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
-
Patent number: 10046024Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.Type: GrantFiled: June 28, 2016Date of Patent: August 14, 2018Assignee: The United States of America, as represented by National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resource (DEITR)Inventors: Mark Spaller, John Marshall, Dennis J. Goebel
-
Patent number: 10046025Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a cyclic polypeptide.Type: GrantFiled: September 13, 2016Date of Patent: August 14, 2018Assignee: Aegis Therapeutics, LLCInventor: Edward T. Maggio
-
Patent number: 10046026Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.Type: GrantFiled: October 5, 2015Date of Patent: August 14, 2018Assignee: The Johns Hopkins UniversityInventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
-
Patent number: 10046027Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: December 28, 2015Date of Patent: August 14, 2018Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 10046028Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.Type: GrantFiled: April 20, 2016Date of Patent: August 14, 2018Assignee: Sangamo Therapeutics, Inc.Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
-
Patent number: 10046029Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.Type: GrantFiled: December 10, 2013Date of Patent: August 14, 2018Inventor: Martin Roecken
-
Patent number: 10046030Abstract: The present invention encompasses compositions and methods useful to treat or prevent Clostridium difficile antibiotic-associated colitis through administration of IL-25 and/or downstream cytokines IL-13, IL-4, and IL-5. It is disclosed herein that IL-25 expression is decreased during antibiotic treatment and during bacterial infection and that treatment with IL-25 protein is protective during infection. It is further disclosed herein the unexpected result that IL-25 treatment protects against C. difficile-associated mortality and morbidity. The present application further describes an unexpected result regarding eosinophils and their role in combating infection and their relationship to the effectiveness of IL-25.Type: GrantFiled: October 7, 2015Date of Patent: August 14, 2018Assignee: University of Virginia Patent FoundationInventors: William A. Petri, Jr., Erica Buonomo
-
Patent number: 10046031Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: GrantFiled: February 1, 2017Date of Patent: August 14, 2018Assignee: MannKind CorporationInventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
-
Patent number: 10046032Abstract: The present disclosure provides means and methods for promoting gastric emptying. In particular, the present disclosure provides the use of insulin or a composition comprising same for promoting gastric emptying and for treating gastric disorders, particularly disorders characterized by delayed gastric emptying. The insulin or composition comprising same are to be administered enterally.Type: GrantFiled: March 24, 2017Date of Patent: August 14, 2018Assignee: Nutrinia, LTD.Inventors: Tal Atarot, Michal Olshansky
-
Patent number: 10046033Abstract: The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.Type: GrantFiled: June 24, 2016Date of Patent: August 14, 2018Assignee: Amicus Therapeutics, Inc.Inventors: Kenneth Valenzano, John Crowley, Richie Khanna, John Flanagan
-
Patent number: 10046034Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.Type: GrantFiled: March 21, 2017Date of Patent: August 14, 2018Assignee: BIOM'UPInventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
-
Patent number: 10046035Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.Type: GrantFiled: July 5, 2017Date of Patent: August 14, 2018Assignee: SYNTHETIC BIOLOGICS, INC.Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
-
Patent number: 10046036Abstract: The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.Type: GrantFiled: August 12, 2016Date of Patent: August 14, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Jan P Kraus, Tomas Majtan, Erez Bublil
-
Patent number: 10046037Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: August 2, 2016Date of Patent: August 14, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Patent number: 10046038Abstract: The antigenic mass of Leptospira cultures can be significantly increased, independent from any increase in biomass, by supplementing Leptospira cultures with a specific type of fatty acid: a polyunsaturated C18 fatty acid. This provides advantages in the production Leptospira antigens. Also this enables the production of improved Leptospirosis vaccines, that are safer and more effective.Type: GrantFiled: December 20, 2013Date of Patent: August 14, 2018Assignee: Intervet Inc.Inventors: Christian Theodoor Gerardus Smits, Edwin Kets, Henriette Adriaanse
-
Patent number: 10046039Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: GrantFiled: August 19, 2014Date of Patent: August 14, 2018Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Patent number: 10046040Abstract: The invention relates to a multivalent Clostridium difficile vaccine comprising a Salmonella Typhi live vector comprising the cell binding domain of TcdA toxin (CBD/A) of Clostridium difficile or an antigenic fragment thereof and the cell binding domain of TcdB toxin (CBD/B) of Clostridium difficile or an antigenic fragment thereof and optionally the cell-binding subunit component (CdtB) of binary toxin of Clostridium difficile or an antigenic fragment thereof. The invention further provides methods of inducing an immune response and methods of preventing recurrence of C. difficile infections in subjects.Type: GrantFiled: November 16, 2010Date of Patent: August 14, 2018Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventor: James E. Galen
-
Patent number: 10046041Abstract: The present invention is directed to methods of suppressing the virulence of one or more virulence antigenic factors of methicillin resistant Staphylococcus aureus (MRSA). Aspects of the invention include administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of a virulence antigenic factor of MRSA attached through a linker to the aminoterminal end of the ecd CD40 ligand. The fusion protein is composed of a virulence antigenic factor of MRSA and CD40 ligand and has the ability to generate antibodies which prevents host cell infection by suppressing virulence functions of MRSA.Type: GrantFiled: December 22, 2016Date of Patent: August 14, 2018Assignee: MicroVAX, LLCInventor: Albert B. Deisseroth
-
Patent number: 10046042Abstract: The present invention provides a meningococcal conjugate vaccine for groups A, C, Y and W135, which is a tetravalent conjugate vaccine comprising polysaccharide-protein conjugates obtained by respectively conjugating a capsular polysaccharide of Neisseria meningitides groups A, C, Y and W135 to a outer membrane vesicle protein selected from a group consisting of Neisseria meningitides group B serotypes 4 and 15 outer membrane vesicle proteins.Type: GrantFiled: June 29, 2016Date of Patent: August 14, 2018Assignee: Beijing Sanroad Biological Products Co., Ltd.Inventor: Wang Jianhua